Show simple item record

dc.contributor.authorPiggott, L
dc.contributor.authorda Silva, A
dc.contributor.authorRobinson, T
dc.contributor.authorSantiago-Gómez, Angélica
dc.contributor.authorSimões, Bruno M
dc.contributor.authorBecker, M
dc.contributor.authorFichtner, I
dc.contributor.authorAndera, L
dc.contributor.authorPiva, M
dc.contributor.authorVivanco, M
dc.contributor.authorMorris, C
dc.contributor.authorAlchami, F
dc.contributor.authorYoung, P
dc.contributor.authorBarrett-Lee, P
dc.contributor.authorClarke, Robert B
dc.contributor.authorGee, J
dc.contributor.authorClarkson, R
dc.date.accessioned2018-03-14T08:49:50Z
dc.date.available2018-03-14T08:49:50Z
dc.date.issued2018-01-23
dc.identifier.citationAcquired resistance of ER- positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through post-translational downregulation of c-FLIP. 2018 Clin. Cancer Res.en
dc.identifier.issn1078-0432
dc.identifier.pmid29363524
dc.identifier.doi10.1158/1078-0432.CCR-17-1381
dc.identifier.urihttp://hdl.handle.net/10541/620830
dc.description.abstractOne-third of ER-positive breast cancer patients who initially respond to endocrine therapy become resistant to treatment. Such treatment failure is associated with poor prognosis and remains an area of unmet clinical need.  Here we identify a specific post-translational modification that occurs during endocrine resistance and which results in tumour susceptibility to the apoptosis inducer TNF-Related Apoptosis-Inducing Ligand (TRAIL). This potentially offers a novel stratified approach to targeting endocrine resistant breast cancer.
dc.language.isoenen
dc.rightsArchived with thanks to Clinical cancer research : an official journal of the American Association for Cancer Researchen
dc.titleAcquired resistance of ER- positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through post-translational downregulation of c-FLIP.en
dc.typeArticleen
dc.contributor.departmentEuropean Cancer Stem Cell Research Institute, Cardiff University piggottl@Cardiff.ac.ukEuropean Cancer Stem Cell Research Institute, Cardiffen
dc.identifier.journalClinical Cancer Researchen
refterms.dateFOA2020-04-20T15:24:08Z
html.description.abstractOne-third of ER-positive breast cancer patients who initially respond to endocrine therapy become resistant to treatment. Such treatment failure is associated with poor prognosis and remains an area of unmet clinical need.  Here we identify a specific post-translational modification that occurs during endocrine resistance and which results in tumour susceptibility to the apoptosis inducer TNF-Related Apoptosis-Inducing Ligand (TRAIL). This potentially offers a novel stratified approach to targeting endocrine resistant breast cancer.


Files in this item

Thumbnail
Name:
560098.pdf
Size:
1.561Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record